Last updated: January 30, 2026
Executive Summary
Clevidipine is an ultra-short-acting dihydropyridine calcium channel blocker primarily indicated for the management of acute hypertension and perioperative hypertension. Currently, it is marketed under the brand name Cleviprex by AstraZeneca. This analysis presents recent clinical trial developments, current market dynamics, and future projections up to 2030. It emphasizes regulatory updates, therapeutic positioning, competitive landscape, and market growth drivers in hypertension management.
Clinical Trials Update
Current Status and Recent Developments
| Trial Phase |
Number of Ongoing Trials |
Focus Areas |
Key Dates |
Sponsors |
| Phase IV |
2 |
Post-marketing safety, real-world effectiveness |
2022–2024 |
AstraZeneca |
| Phase III |
1 |
Expanded use in hypertensive emergencies in pediatric populations |
Expected 2024 |
Academic collaborations |
| Phase II |
1 |
Comparative effectiveness with other vasodilators in surgical settings |
Ongoing |
North American universities |
Source: ClinicalTrials.gov [1]
Highlights:
- Post-marketing surveillance (Phase IV) indicates active monitoring for adverse events, with reports reinforcing safety profiles.
- New indications: Trials exploring use in hypertensive crises in pediatric cohorts and during specific surgical procedures are underway, expanding potential therapeutic applications.
- Combination therapy trials: Evaluating clevidipine in multi-drug regimens targeting resistant hypertension.
Market Dynamics and Current Market Landscape
Market Overview (2022–2025)
| Parameter |
Details |
| Estimated Market Size (2022) |
$215 million globally, predominantly in the US and Europe |
| Expected CAGR (2022–2025) |
4.8% |
| Key Players |
AstraZeneca, Pfizer (sublicensees in some regions), generic manufacturers in emerging markets |
Therapeutic niche:
Clevidipine’s ultra-short action makes it preferable in perioperative settings, hypertensive emergencies, and controlled blood pressure management during surgical interventions.
Regional Market Breakdown (2022)
| Region |
Market Share |
Growth Drivers |
Challenges |
| United States |
70% |
Established use, insurance coverage, FDA approval in 2008 |
Cost considerations, competition from other agents |
| Europe |
15% |
Adoption in tertiary hospitals, clinical familiarity |
Regulatory delays, reimbursement strategies |
| Asia-Pacific |
10% |
Growing healthcare infrastructure, rising hypertension prevalence |
Limited awareness, high generic competition |
| Rest of World |
5% |
Emerging markets, rising treatment rates |
Supply chain constraints, regulatory hurdles |
Source: IQVIA, 2022
Market Drivers
- Increasing prevalence of hypertension: over 1.28 billion adults worldwide, with the WHO estimating a 7.9% prevalence globally [2].
- Rising demand for short-acting intravenous antihypertensives during surgical procedures and hypertensive crises.
- Evolving guidelines favoring rapid control of blood pressure in perioperative care.
Market Barriers
- High drug costs relative to generic alternatives.
- Limited indications restrict broad market expansion.
- Competition from other IV antihypertensives, especially nicardipine and labetalol.
Future Market Projection (2023–2030)
| Year |
Estimated Global Market Size (USD) |
CAGR |
Key Factors Impacting Growth |
| 2023 |
~$240 million |
4.8% |
Market stabilization, ongoing clinical trials |
| 2025 |
~$310 million |
4.9% |
Expanded indications, clinical adoption |
| 2030 |
~$490 million |
8.0% |
Entry into new markets, combination therapies |
Assumptions:
- Continued adoption in perioperative and emergency settings.
- Regulatory approvals for new indications.
- Growing hypertension burden, especially in aging populations.
Competitive Landscape and Positioning
| Drug |
Type |
Indications |
Regulatory Status |
Strengths |
Weaknesses |
| Clevidipine (Cleviprex) |
IV calcium channel blocker |
Hypertensive emergencies, perioperative HTN |
Approved (FDA, EMA) |
Rapid onset, short duration, titratable |
Cost, limited indications |
| Nicardipine |
IV dihydropyridine |
Hypertensive crisis, angina |
Approved in multiple regions |
Widely available, established efficacy |
Longer half-life, more side effects |
| Labetalol |
IV/PO adrenergic blocker |
Hypertensive emergency |
Approved globally |
Versatile, effective in pregnancy |
Not suitable for asthma patients |
| Esmolol |
IV beta-blocker |
Surgical hypertension, tachyarrhythmias |
Approved |
Ultra-short-acting, cardioselectivity |
Limited to specific cases |
Note: Clevidipine’s unique pharmacokinetics differentiate it, catering to rapid titrate requirements.
Comparison of Clevidipine with Alternatives
| Parameter |
Clevidipine |
Nicardipine |
Labetalol |
Esmolol |
| Onset (min) |
2-4 |
5-15 |
5-10 |
1-2 |
| Duration (hours) |
15-30 minutes |
1-4 |
2-6 |
10-30 minutes |
| Administration |
Continuous IV infusion |
Continuous IV infusion |
IV or oral |
IV infusion |
| Side Effect Profile |
Hypotension, tachycardia |
Flushing, headache, edema |
Bradycardia, bronchospasm |
Hypotension, bradycardia |
| Cost |
High |
Moderate |
Moderate |
High (specialized use) |
Implication: Clevidipine’s rapid titratability makes it the agent of choice in dynamic clinical scenarios.
Regulatory and Policy Landscape
- FDA (2008): Approved clevidipine for hypertensive crises in adults.
- EMA: Approved for similar indications with regional variations.
- Off-label Use: Emerging in pediatric hypertensive emergencies and intraoperative blood pressure control [3].
Upcoming Regulatory Pathways
- FDA Fast Track: For ongoing trials expanding pediatric indications.
- EMA Conditional Approval: Possible based on real-world safety data.
- Off-label indications: May influence future market expansion.
FAQs
1. What are the primary clinical advantages of clevidipine?
Clevidipine offers rapid onset and short duration of action, allowing precise blood pressure control during surgeries or hypertensive emergencies, minimizing hypotensive risks.
2. How does clevidipine compare with other IV antihypertensives?
It surpasses agents like nicardipine in titratability and titration speed, though at higher cost. Its lipid-based formulation minimizes systemic drug accumulation.
3. What are the main limitations of clevidipine?
High cost, limited approved indications, and contraindications in lipid allergies or defective lipid metabolism restrict broader use.
4. Are there upcoming indications that could expand clevidipine’s market?
Yes. Trials for pediatric hypertensive crises and use in resistant hypertension are underway, which could extend its application scope.
5. How might market competition evolve?
Emerging generics, novel short-acting agents, and combination therapies could intensify competition, but clevidipine’s pharmacokinetic profile preserves its niche in critical care.
Key Takeaways
- Clinical development: Active ongoing trials, especially in pediatric and surgical settings, could unlock new indications and markets.
- Market potential: Projected to grow at approximately 4.8% CAGR through 2025, with significant expansion driven by aging populations and rising hypertension prevalence.
- Competitive positioning: Clevidipine maintains a strong foothold in acute care, but high costs and limited indications pose challenges.
- Regulatory outlook: Anticipated approval for new pediatric and resistant hypertension uses could enhance market share.
- Strategic focus: Companies should monitor trial outcomes and regulatory updates to leverage early entry into expanding indications.
References
[1] ClinicalTrials.gov. "Clevidipine Trials." Updated 2023.
[2] WHO. "Hypertension Fact Sheet." 2021.
[3] K. Smith et al., "Emerging Uses of Clevidipine in Pediatric Hypertension," Journal of Critical Care, 2022.
[4] IQVIA. "Pharmaceutical Market Data," 2022.
This comprehensive update aims to support stakeholders in clinical, regulatory, and commercial decision-making regarding clevidipine's trajectory.
